Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 14/20 | 1.00 |
| ▸ | LPAR1 | Q92633 | 13/20 | 1.00 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.72 |
| ▸ | LPAR5 | Q9H1C0 | 6/20 | 0.69 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.56 |
| ▸ | LPAR4 | Q99677 | 5/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.51 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29458233 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL29353224 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL31439420 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL30443866 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL31198159 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL10896195 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL2813163 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL2814732 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL5055004 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL27734843 | 1.00 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8106032-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100249055-A1 | CLOFARABINE PHOSPHOLIPID DERIVATIVES | HEIDELBERG PHARMA AG (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20080293667-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2008-11-27 | — | — | US | disclosed |
| EP-0781138-B1 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | UNIV WAKE FOREST (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7294621-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294620-B2 | Lipid analogs for inhibiting HIV-1 activity | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294619-B2 | Lipid analogs for inhibiting the activity of hepatitis B antigen | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1852121-A2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070105812-A1 | Lipid analogs for inhibiting HIV-1 activity | WAKE FOREST UNIVERSITY | 2007-05-10 | — | — | US | disclosed |
| US-20050080050-A1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040259845-A1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY | 2004-12-23 | — | — | US | disclosed |
| EP-0702556-B1 | (PHOSPHO)LIPIDS FOR COMBATTING HEPATITIS B VIRUS INFECTION | UNIV WAKE FOREST (US) | 2002-10-23 | — | — | EP | disclosed |
| US-6030960-A | INHIBITING THE PRODUCTION OF HEPATITIS VIRUS-INDUCED ANTIGENS IN A HUMAN SUBJECT BY ADMINISTERING A COMPOUND | WAKE FOREST UNIVERSITY (US) | 2000-02-29 | — | — | US | disclosed |
| US-5962437-A | HEPATITIS, HERPES AND AIDA VIRUS | WAKE FOREST UNIVERSITY (US) | 1999-10-05 | — | — | US | disclosed |
| US-5770584-A | ADMINISTERING AN ALKYL LIPID OR ALKYL LIPID DERIVATIVE VIRICIDES | WAKE FOREST UNIVERSITY (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0781138-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1997-07-02 | — | — | EP | disclosed |
| EP-0702556-A1 | (PHOSPHO)LIPIDS FOR COMBATTING HEPATITIS B VIRUS INFECTION | WAKE FOREST UNIVERSITY (US) | 1996-03-27 | — | — | EP | disclosed |
| WO-1996006620-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1996-03-07 | — | — | WO | disclosed |
| WO-1994028908-A2 | (PHOSPHO)LIPIDS FOR COMBATTING HEPATITIS B VIRUS INFECTION | WAKE FOREST UNIVERSITY (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | NUDT1, DUT, ADAR | LPAR3 2508/4885LPAR1 2561/4885LPAR2 3158/4885 |
| US-20070105812-A1 | Lipid analogs for inhibiting HIV-1 activity | SGMS1, HDLBP, LIPC | LPAR3 142/4885LPAR1 64/4885LPAR2 125/4885 |
| US-20040259845-A1 | Lipid analogs for treating viral infections | SGMS1, PHOSPHO1, SGMS2 | LPAR3 146/4885LPAR1 83/4885LPAR2 149/4885 |
| US-20050080050-A1 | Lipid analogs for treating viral infections | SGMS1, PHOSPHO1, SGMS2 | LPAR3 146/4885LPAR1 83/4885LPAR2 149/4885 |
| US-20080293667-A1 | Lipid analogs for combating tumors | SGMS1, PNLIP, SGMS2 | LPAR3 48/4885LPAR1 32/4885LPAR2 34/4885 |
| US-20100249055-A1 | CLOFARABINE PHOSPHOLIPID DERIVATIVES | PHOSPHO1, ABHD16A, SGMS2 | LPAR3 307/4885LPAR1 315/4885LPAR2 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.